Biotechnology

Found 8,688 articles

• GeoVax HIV Clinical Trials Update

  11/15/2017

  GeoVax Labs today announced that the HIV Vaccine Trials Network has closed enrollment for the phase 1 human clinical trial evaluating late boosts of GeoVax's preventive vaccine (GOVX-B11) for clade B HIV.

• Enrollment of First Cohort Completed With Eighth Participant Dosed in Cynata’s World First Clinical Trial

  11/15/2017

  Enrollment of the first cohort (Cohort A) is now complete. Participants in Cohort A received two CYP-001 infusions each at the lower dose level (1 million cells/kg, up to a maximum of 100 million cells per infusion).

• BioTime Presents Updated OpRegen Phase I/IIa Trial Data at AAO

  11/15/2017

  There were no treatment-related serious adverse events after 15 months.

• Imcyse Continues Patient Enrolment in its Phase Ib Trial in Type 1 Diabetes

  11/15/2017

  The trial is now recruiting patients at 15 clinical sites in four European countries and should open soon in France.

• Onconova Therapeutics Announces Publication of Results From Phase I/II Study of Rigosertib in Patients with Myelodysplastic Syndromes (MDS) and MDS Progressed to Acute Myeloid Leukemia

  11/15/2017

  This study was conducted at the Mount Sinai School of Medicine, under the guidance of Dr. Lewis Silverman, a pioneer in developing treatments for patients with Higher-risk MDS.

• Preclinical Data Demonstrates Potential of Eidos Therapeutics' Lead Compound for the Treatment for Transythyretin Amyloidosis

  11/15/2017

  These data were shared publicly for the first time yesterday as oral podium presentations at the AHA 2017 Annual Scientific Sessions in Anaheim, CA.

• Navitor Pharmaceuticals to Develop NV-5138, a Specific Activator of mTORC1 for Treatment-Resistant Depression, Based on Promising Data Presented at Society for Neuroscience 2017

  11/15/2017

  First data on NV-5138 demonstrating direct mTORC1 activation resulting in ketamine-like rapid antidepressant effects in preclinical animal models.

• Preclinical Studies with MyoKardia’s Mavacamten Demonstrate Evidence of Reduced Contractility and Improved Left Ventricular Compliance

  11/15/2017

  Data from MyoKardia’s in vivo study demonstrated that treatment with mavacamten improved myocardial compliance while preserving systemic pressures.

• Macrogen's Clinical NGS Laboratory Receives CAP Accreditation

  11/15/2017

  The accreditation was based on results of a recent on-site inspection as part of the CAP’s Accreditation Programs.

• Inotrem Granted Access to Priority Medicines Scheme (PRIME) for Its Lead Compound MOTREM in the Treatment of Septic Shock

  11/15/2017

  The EMA’s PRIME status is granted to promising medicines that may offer a major therapeutic advantage over existing treatments or benefit patients with no treatment options.

• Phase III Trial With Zepsyre in Small-Cell Lung Cancer (ATLANTIS) to Continue on the Basis of Positive Recommendation by IDMC

  11/15/2017

    [15-November-2017]   MADRID, November 15, 2017 /PRNewswire/ -- PharmaMar (MCE:PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has notified the Company of its recommendation that the Phase III (ATLANTIS) trial currently under way with Zepsyre(R) (PM1183) in combination with doxorubicin in small-cell lung cancer patients should continue without

• Kalytera Announces Notice of Allowance of US Patent for Treatment of Graft Versus Host Disease

  11/15/2017

  Securing a patent for this proprietary technology represents an important step forward for the Company in its work focused on the treatment of this serious and life-threatening disease.

• ADMA Biologics Further Enhances Intellectual Property Portfolio Through Newly Issued U.S. Patent for Immunotherapeutic Compositions

  11/15/2017

  The term of the issued patent extends to January 2035.

• Immuron Granted U.S. Patent for NASH Treatment

  11/15/2017

  The patent comprises of a total of ten allowed claims, and is principally directed to a method of treating non-alcoholic steatohepatitis (NASH) with a colostrum-based composition, as developed by Immuron.

• Quanta Introduces Polarized Cannabis

  11/15/2017

  Quanta, a biotech firm specializing in resonance energy, today announced the launch of its patented technology into the cannabis industry.

• Ampio Announces Start of Open Label Extension Study to Support Commercial Label of Repeat Administration of Ampion in Severe Osteoarthritis of the Knee

  11/15/2017

  The OLE study offers patients an opportunity to receive repeat injections of Ampion after they have completed the pivotal clinical trial.

• Oncodesign Announces Positive Results Opening the Way for The ALK1 Program to Advance to the Lead Optimization Phase

  11/15/2017

  The company has obtained positive results opening the way for the ALK1 kinase inhibitor discovery program to move on to the lead optimization phase.

• Amarin: Real World Data Analysis Shows That Persistent Hypertriglyceridemia Despite Statin Therapy is Associated With Cardiovascular Risk

  11/15/2017

  This analysis of RWE is separate from and independent of the RWE analysis referenced in Amarin’s press release on November 12, 2017.

• BMG Pharma is Pleased to Announce Positive Clinical Results on GelX the First Breakthrough Product to Achieve Prevention of Oral Mucositis in Cancer Patients

  11/15/2017

  The new clinical data, (conducted under GCP principles) from 149 adult and paediatric patients has shown unique results for the first time, with 36,2% of the patients having a complete prevention of oral mucositis during cancer therapy.

• Tempus Announces Latest Immunotherapy Project

  11/15/2017

  The company announced a new research collaboration aimed at identifying which patients will respond positively to immunotherapy treatment, the next generation of cancer care.